Summary
Imaging is increasingly used to inform the drug development process, and provides valuable information from preclinical testing to clinical trials. The challenge is for imaging techniques to yield robust and reproducible measurements, which can indicate early treatment response or identify patients who are likely to respond to treatment. This allows timely decisions to be made, so that the development of the most promising drugs can be accelerated, while curtailing the development of treatments with doubtful clinical benefits. DW-MRI is one of a number of imaging methodologies which, when further developed and applied appropriately, could represent a major improvement over current imaging or other endpoints used to evaluate the success of therapy. In this chapter, we discuss the challenges faced by modern day drug development and review the process from concept to commercialization of drug therapies. The important role of imaging in this process is discussed, including the development of DW-MRI as a potential biomarker or surrogate study endpoint, and the challenges that need to be addressed to enable realization of such a goal.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adams C P, Brantner VV (2006) Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood) 25:420–8
Adjei AA, Christian M, Ivy P (2009) Novel designs and end points for phase II clinical trials. Clin Cancer Res 15:1866–72
Atkinson AJ, et al (2001) Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95
Berry LR, et al (2008) Quantification of viable tumor micro-vascular characteristics by multispectral analysis. Magn Reson.Med 60:64–72
Booth B, Glassman R, Ma P (2003) Oncology's trials. Nat Rev Drug Discov 2:609–10
Dancey JE, Chen HX (2006) Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 5:649–59
Dhani N, et al (2009) Alternate endpoints for screening phase II studies. Clin Cancer Res 15:1873–82
DiMasi JA, Grabowski HG (2007a) Economics of new oncology drug development. J Clin Oncol 25:209–16
DiMasi JA, Grabowski HG (2007b) The cost of biopharmaceu-tical R&D: is biotech different? Managerial Decision Econ 28:469–79
DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22:151–85
Dzik-Jurasz A, et al (2002) Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 360:307–8
El Maraghi RH, Eisenhauer EA (2008) Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. J Clin Oncol 26:1346–54
FDA (2004) Innovation stagnation: challenge and opportunity on the critical path to new medicines. FDA, USA
FDA (2006) Critical path opportunities initiated during 2006. FDA, USA
Galons J P, et al (1999) Early increases in breast tumor xeno-graft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia 1:113–17
Hamstra DA, et al (2005) Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A 102:16759–64
Jennings D, et al (2002) Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI. Neoplasia 4:255–62
Jordan BF, Runquist M, Raghunand N, et al (2005) Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironmentin response to inhibition of HIF-1alpha using PX-478. Neoplasia 7:475–85
Kamb A (2005) What's wrong with our cancer models? Nat Rev Drug Discov 4:161–5
Kamb A, Wee S, Lengauer C (2007) Why is cancer drug discovery so difficult? Nat Rev Drug Discov 6:115–20
Padhani AR, et al (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11:102–25
Pharmaceutical Research and Manufacturers of America (2009) 2009 Report medicines in development for cancer
Rowinsky EK (2004) Curtailing the high rate of late-stage attrition of investigational therapeutics against unprecedented targets in patients with lung and other malignancies Clin Cancer Res 10:4220S–26S
Wagner JA (2002) Overview of biomarkers and surrogate endpoints in drug development. Dis Markers 18:41–6
Wagner JA, Williams SA, Webster CJ (2007) Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther 81:104–7
Walker I, Newell H (2009) Do molecularly targeted agents in oncology have reduced attrition rates? Nat Rev Drug Discov 8:15–16
Weber WA (2009) Assessing tumor response to therapy. J Nucl Med 50(Suppl 1):1S–10S
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Dzik-Jurasz, A., Murphy, P. (2010). The Potential of DW-MRI as an Imaging Biomarker in Clinical Trials. In: Koh, D.M., Thoeny, H.C. (eds) Diffusion-Weighted MR Imaging. Medical Radiology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-78576-7_16
Download citation
DOI: https://doi.org/10.1007/978-3-540-78576-7_16
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-78575-0
Online ISBN: 978-3-540-78576-7
eBook Packages: MedicineMedicine (R0)